US 11,851,655 B2
Compositions and methods for modulating apolipoprotein (a) expression
Thazha P. Prakash, Carlsbad, CA (US); Punit P. Seth, Carlsbad, CA (US); Eric E. Swayze, Encinitas, CA (US); and Mark J. Graham, San Clemente, CA (US)
Assigned to Ionis Pharmaceuticals, Inc., Carlsbad, CA (US)
Filed by Ionis Pharmaceuticals, Inc., Carlsbad, CA (US)
Filed on Oct. 1, 2020, as Appl. No. 17/060,440.
Application 17/060,440 is a continuation of application No. 15/891,156, filed on Feb. 7, 2018, granted, now 10,883,104.
Application 15/891,156 is a continuation of application No. 14/839,580, filed on Aug. 28, 2015, granted, now 9,957,504, issued on May 1, 2018.
Application 14/839,580 is a continuation of application No. 14/588,061, filed on Dec. 31, 2014, granted, now 9,181,550, issued on Nov. 10, 2015.
Application 14/588,061 is a continuation of application No. PCT/US2014/036460, filed on May 1, 2014.
Claims priority of provisional application 61/986,867, filed on Apr. 30, 2014.
Claims priority of provisional application 61/976,991, filed on Apr. 8, 2014.
Claims priority of provisional application 61/880,790, filed on Sep. 20, 2013.
Claims priority of provisional application 61/871,673, filed on Aug. 29, 2013.
Claims priority of provisional application 61/843,887, filed on Jul. 8, 2013.
Claims priority of provisional application 61/823,826, filed on May 15, 2013.
Claims priority of provisional application 61/818,442, filed on May 1, 2013.
Prior Publication US 2021/0087566 A1, Mar. 25, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07H 21/02 (2006.01); C07H 21/04 (2006.01); C12N 15/113 (2010.01); A61K 47/54 (2017.01); C12N 15/11 (2006.01); A61K 31/7088 (2006.01); A61K 31/713 (2006.01)
CPC C12N 15/113 (2013.01) [A61K 31/7088 (2013.01); A61K 31/713 (2013.01); A61K 47/549 (2017.08); C07H 21/04 (2013.01); C12N 15/111 (2013.01); C12N 2310/11 (2013.01); C12N 2310/113 (2013.01); C12N 2310/17 (2013.01); C12N 2310/31 (2013.01); C12N 2310/315 (2013.01); C12N 2310/321 (2013.01); C12N 2310/322 (2013.01); C12N 2310/3231 (2013.01); C12N 2310/3341 (2013.01); C12N 2310/341 (2013.01); C12N 2310/346 (2013.01); C12N 2310/351 (2013.01); C12N 2310/353 (2013.01); C12N 2310/3511 (2013.01); C12N 2310/3513 (2013.01); C12N 2310/3515 (2013.01); C12N 2310/3525 (2013.01); C12N 2320/32 (2013.01)] 33 Claims
 
1. A compound or a salt thereof comprising a modified oligonucleotide and a conjugate group, wherein the modified oligonucleotide consists of 12 to 30 linked nucleosides and comprises a nucleobase sequence comprising a portion of at least 8 contiguous nucleobases complementary to an equal length portion of nucleobases 3901 to 3920 of SEQ ID NO: 1, wherein the nucleobase sequence of the modified oligonucleotide is at least 80% complementary to SEQ ID NO: 1; and wherein the conjugate group comprises:

OG Complex Work Unit Chemistry
wherein each n is, independently, an integer from 1 to 20.